Scherzer is obviously a legend in the game and a future Hall of Famer. He debuted back in 2008, has almost 3,000 innings in the majors with a 3.16 earned run average, three Cy Young trophies, eight All-Star selections and two World Series rings.

The question is what he has left in the tank at this point. He is now 40 years old and coming off an injury-marred season. He started 2024 on the injured list while recovering from offseason back surgery. Though he recovered from that, he also battled a nerve issue in his hand, shoulder fatigue and a strained hamstring throughout the season. He was limited to just nine starts and 43 1/3 innings.

That obviously creates some concern but Scherzer has been remarkably durable throughout his career. In each full season from 2009 to 2023, he made 27 or more starts and logged at least 145 1/3 innings. From 2013 to 2018, he had six straight seasons of hitting the 200-inning plateau. In short, 2024 was the first season of his career where he missed significant time.

Even though the volume of his output was low, some of the results last year were still decent. He posted a 3.95 earned run average over those nine starts. His 22.6% strikeout rate was a drop for him personally but still around league average, while his 5.6% walk rate was still a very strong mark. His velocity was down as well on his fastball, going from 93.7 miles per hour in 2023 to 92.5 mph last year.

There are obviously some yellow flags in there but it’s of course possible that better health could lead to some better results. It’s a bit of a gamble for the Jays but this is clearly the market rate for a veteran pitcher with some question marks. Each of Justin Verlander, Charlie Morton and Alex Cobb secured one-year deals worth $15MM this offseason. Scherzer symbolically got past that group with an extra half mil.

There are many ways in which Verlander and Scherzer are similar, given their lengthy careers full of accolades. The two have also crossed paths many times, as they were both in the Detroit rotation just over a decade ago, before reuniting with the Mets more recently. Verlander’s 2024 was also injury-marred, though with perhaps some more concerning numbers. His 17 starts and 90 1/3 innings were more than Scherzer managed but Verlander had a 5.48 ERA and his strikeout rate dropped all the way to 18.7%. Verlander is also a bit older, about to turn 42 next month.

Cobb is only 37 but he only managed three starts last year, plus two more in the playoffs, thanks to his own maladies. He also doesn’t quite have the same legendary track record as Scherzer or Verlander. Morton, who is now 41, managed to make 30 starts for Atlanta last year but he seemingly limited his market by having a preference for clubs with spring training sites near his family in Florida.

The Jays have been connected to just about every available free agent this winter. That has included some high-profile position players like Juan Soto, Alex Bregman and Pete Alonso, as well as starting pitchers like Roki Sasaki, Max Fried and Corbin Burnes. There were obviously some frustrating misses in there, but the club has had a couple of strikes more recently. In the past three weeks, they’ve added Anthony Santander to their lineup, Jeff Hoffman to their bullpen and now Scherzer to the rotation.

While the Jays may have preferred to get one of those other starting pitchers, Scherzer keeps their commitment short. It also gives the club a very veteran rotation core. Kevin Gausman is 34, Chris Bassitt will turn 36 next month and José Berríos will be 31 in May. Those four are sure to be taking the ball with regularity, as long as they’re all healthy.

If Scherzer avoids the injury bug this year, he’ll upgrade the rotation and could perhaps indirectly upgrade the bullpen as well. Prior to this signing, Bowden Francis and Yariel Rodríguez were projected as the top options for the fourth and final spots in the rotation. Even with Scherzer in the fold, Francis will likely still get a rotation spot. After the Jays traded Yusei Kikuchi at the deadline last year, Francis got a rotation audition and ran with it. He finished out the campaign with 59 innings over nine starts with a 1.53 ERA, 26.5% strikeout rate and 3.3% walk rate. He still has one minor league option but the Jays would surely like to see if he could carry that forward.

That could push Rodríguez into a relief role, something he has done with success before. Last year was his first in the majors and he made 21 starts with decent results. He had a 4.47 ERA, 23.1% strikeout rate and 10.9% walk rate. But prior to signing with the Jays, he was a dominant closer in Japan. In 2022, he made 56 appearances for the Chunichi Dragons with a 1.15 ERA, 27.5% strikeout rate and 8.3% walk rate. He sat out 2023 while attempting to be declared a free agent.

Going into last year, Shi Davidi of Sportsnet reported that Rodríguez’s contract stipulated he could only be optioned for the 2024 season. The Blue Jays did indeed option him a few times last year but it seems they won’t be able to do so from now on, so perhaps he’ll end up in the bullpen instead. He could compete for a leverage role alongside Hoffman, Yimi García, Chad Green and Erik Swanson.

That would subtract from the rotation depth a bit, but the Jays have a few more options there than they did last year. They added Jake Bloss, who already has a bit of Triple-A and MLB experience, in the aforementioned Kikuchi deal. Adam Macko is on the 40-man roster and should be in Triple-A this year after spending most of 2024 in Double-A. Alek Manoah had internal brace surgery in June and could make a late-season return. Since Scherzer is one a one-year deal and Bassitt is going into the final year of his pact, there are long-term openings for that group if any of them have a good showing in 2025.

RosterResource now sets the club’s payroll at $250MM and and their competitive balance tax number at $273MM. That puts them already well beyond last year’s Opening Day payroll, which Cot’s Baseball Contracts put at $225MM. Their CBT number was over the line in 2024 but they ducked under when their disappointing season lead to a deadline selloff, so they will go into 2025 as “first-time” payors. They are now within striking distance of the third CBT line, which will be $281MM next year. Going over that marker this year would mean their top pick in the 2026 draft would be pushed back 10 spots.

Despite running those numbers up to new heights, it doesn’t appear they are done. Per Bob Nightengale of USA Today, the Jays are still interested in Pete Alonso if he doesn’t circle back to the Mets while Keegan Matheson of MLB.com also suggests they should still have some flexibility. Maybe the Jays will add Alonso or someone else, or finally get an extension done with Vladimir Guerrero Jr. It’s been a long, frustrating winter for Jays fans but a lot has changed in the past few weeks, perhaps with more to come. Pitchers and catchers report to spring training in about two weeks.

Jon Heyman of The New York Post first reported that Scherzer was headed to the Jays. Bob Nightengale of USA Today first reported that it was a one-year deal. Heyman then reported the $15.5MM guarantee. Ben Nicholson-Smith of Sportsnet first had the lack of deferrals. Heyman had the no-trade clause.

Still, Scherzer has been preparing to pitch in 2025 and recently held a workout for scouts, Mark Feinsand of MLB.com reports. SI.com’s Pat Ragazzo reported recently that the Blue Jays, Dodgers, Yankees, Mets, Phillies, Braves, Red Sox and Cubs were among those who were represented at the showcase. (That’s not necessarily an exhaustive list of teams.)

The Blue Jays have been the team most prominently linked to Scherzer thus far in the offseason, and Feinsand indeed suggests that Toronto has been the most serious suitor for Scherzer. Ragazzo adds that the Mets have “some level of interest” in bringing Scherzer back on a one-year deal. Time will tell whether the right-hander’s recent showcase for scouts drums up any new bidders, but Feinsand quotes one showcase attendee who suggested that Scherzer looked good — not up to his prior Cy Young standards but still “good enough to be an effective starter.”

At least in the 43 1/3 innings Scherzer managed amid all those maladies in 2024, that looked to be the case. In addition to his previously mentioned 3.95 ERA, the right-hander fanned 22.6% of opponents (roughly average) with a terrific 5.6% walk rate. His once-95-mph fastball sat at a career-low average of 92.5 mph in 2024, however, and he dealt with home run troubles for a second straight year (1.65 HR/9 in 2023, 1.45 in 2024). The righty’s swinging-strike rate (14.6%) remained excellent, but most of those whiffs came off the plate. Scherzer’s opponents made contact on 83.1% of swings within the strike zone — his highest level since 2011.

For the Jays, Scherzer wouldn’t need to reprise his status as an ace, however. Kevin Gausman, Chris Bassitt and Jose Berrios have the top three spots in the rotation. Bowden Francis and Yariel Rodriguez follow, but Francis has minor league options remaining and Rodriguez could move back into the bullpen. Toronto’s pitching depth, in general, is somewhat shaky with Alek Manoah on the mend from elbow surgery and top prospect Ricky Tiedemann missing most of the 2024 season due to injury. Rotation candidates beyond the top five include prospects Jake Bloss and Adam Macko as well as non-roster invitees Adam Kloffenstein and Eric Lauer.

The Mets have a more crowded staff, but president of baseball operations David Stearns is known for hoarding depth. Kodai Senga, Sean Manaea, Frankie Montas, David Peterson, Paul Blackburn and reliever-turned-starter Clay Holmes make up the starting staff right now. Swingmen Griffin Canning and Tylor Megill could get looks, too, as could top prospect Brandon Sproat. Fitting Scherzer into the puzzle is a bit of a challenge, particularly given the 110% luxury task the Mets are facing.

The Jays have been linked to dozens of free agents this winter, continuing the unofficial “check in on everyone” strategy that general manager Ross Atkins has broadly used over the last five years, since the team’s rebuilding phase was ended when Hyun-Jin Ryu signed a four-year, $80MM contract.  It therefore isn’t surprising that the Blue Jays also have Scherzer on their radar, both because Toronto is looking for rotation help and because Scherzer has some intriguing buy-low potential given his lengthy resume.

2024 was perhaps the least-noteworthy of Scherzer’s 17 MLB seasons, as he pitched a career-low 43 1/3 innings.  Scherzer underwent back surgery last offseason and was expected to miss at least a bit of time at the start of the 2024 campaign while recovering, but subsequent issues with nerve irritation in his triceps, shoulder fatigue, and a hamstring strain resulted in what was pretty close to a lost season for both Scherzer and the Rangers as a whole.

At least the nerve problem seems to have been corrected by a mechanical change, as Scherzer relayed to reporters last September, and Scherzer is now over a year removed from his back procedure.  While the right-hander has generally been quite durable over his long career, it also wouldn’t be a surprise if the long grind of 2878 big league innings has finally caught up to Scherzer now that he has passed his 40th birthday.

Injuries notwithstanding, Scherzer was still able to post a respectable 3.95 ERA last season.  His walk and chase rates were both excellent in his small sample size of 43 1/3 frames, though that great chase rate manifested itself into only a modest 22.6% strikeout rate.  Scherzer also had a 3.77 ERA over 152 2/3 innings with the Mets and Rangers in 2023, which could be a better reflection of what might be reasonably expected from a healthy Scherzer at this late stage in his career — a solid mid-rotation starter who can still dial up some of his old magic every once in a while.

Scherzer and his former teammate Justin Verlander have often been linked together this winter as veteran superstars coming off injury-marred seasons, and Verlander (entering his age-42 campaign) inked a one-year, $15MM guarantee with the Giants two weeks ago.  With Verlander now off the board, more teams could be looking at Scherzer, even if Toronto is the first club publicly cited as a suitor.

While the Blue Jays signed relievers Jeff Hoffman and Yimi Garcia to multi-year deals this winter, the Jays’ last two offseasons have been defined more by the players the team hasn’t signed rather than the players who actually put pen to paper.  Toronto’s high-profile pursuits of Shohei Ohtani, Juan Soto, Corbin Burnes, Roki Sasaki, and several other top-shelf free agents ended with those players all signing elsewhere, creating the impression that the Jays front office can no longer seal the deal with frontline talent.

It hasn’t helped Atkins’ recruiting efforts that the Blue Jays stumbled to a 74-88 record last season, and finished last place in the AL East.  The possible departures of Vladimir Guerrero Jr. and Bo Bichette into free agency next winter add to the uncertainty over the Jays’ long-term viability as contenders, or even if the team still has enough in the tank to make a rebound in 2025.  “As currently constructed, the Blue Jays might be a tougher sell for” Scherzer, Nicholson-Smith writes, as even if Scherzer’s market might be somewhat limited by his age and recent injuries, he would surely still prefer to play for a contending team if he has options available.

Max Scherzer may be the most intriguing of those short-term targets. The future Hall of Famer was limited to nine starts and 43 1/3 innings during his final season with the Rangers. Scherzer has made clear that he has no plans to retire. He’ll be back for his age-40 campaign in hopes of a healthier, more productive season.

In a live stream for Bleacher Report this afternoon, Jon Heyman suggested that Scherzer is fielding interest from four teams. Heyman indicated that the market “is heating up a bit,” so it’s possible that the three-time Cy Young winner could come off the board in the relatively near future.

Scherzer opened the ’24 season on the injured list as he finished rehab from last December’s back surgery. Nerve irritation in his throwing hand delayed his return until late June. Scherzer made eight starts before going back on the shelf with shoulder fatigue. That kept him out into September. His season concluded after one additional start because of a strained left hamstring.

A pitcher battling multiple injuries, including back surgery, at age 40 is obviously going to raise concerns. Scherzer is only one season removed from starting 30 games and topping 160 innings between the regular season and playoffs. He’d surpassed 170 innings in every full schedule between 2009-21. Until last year, he’d been incredibly durable.

Scherzer remains productive when he’s able to pitch, albeit not at a Cy Young level. He turned in a 3.77 ERA with a 28% strikeout rate between the Mets and Rangers in 2023. Last season, he allowed just under four earned runs per nine with a diminished 22.6% strikeout percentage. Scherzer still got a ton of chases and whiffs on a per-pitch basis though. His 14.6% swinging strike rate ranked fifth among starting pitchers with 40+ innings. Only Blake Snell, Garrett Crochet, Logan Gilbert and Dylan Cease missed bats at a higher rate.

Aside from perhaps Flaherty, Scherzer arguably has the highest ceiling for next season alone of any unsigned starter. There’s also significant risk because of the recent spate of injuries. Scherzer will almost certainly be limited to a one-year contract, so the long-term downside is limited, but he should command a strong salary.

Alex Cobb landed $15MM from the Tigers coming off a season in which he combined for 23 innings between the regular season and playoffs. He recently turned 37 and doesn’t miss bats at anywhere near the rate Scherzer does. It stands to reason that Scherzer and his representation at the Boras Corporation will be aiming to beat Cobb money, perhaps in pursuit of a contract closer to $20MM.

Heyman’s report doesn’t specify any of the teams involved in the bidding. Speculatively speaking, the Braves, Orioles, Blue Jays, Cubs, Nationals and Mets are among the teams that could have some spending room and a desire for a short-term upside play. Scherzer isn’t going to sign with a team that doesn’t have a path to contention, but there are very few truly rebuilding clubs right now. Every team aside from Colorado, Miami and the White Sox may feel they have a path to a Wild Card spot.

Flash forward three years, and things have gone quite well for the first- and second-place finishers for that year’s Cy Young in the NL. Burnes enters this winter as the consensus top free agent pitcher available and could be in line for a guarantee that reaches $200MM, while Wheeler opted against returning to the open market in favor of extending with the Phillies on a three-year, $126MM contract earlier this year and now stands as a Cy Young finalist once again alongside Chris Sale and Paul Skenes. Scherzer and Buehler are also headed into free agency this winter, although neither figures to be in line for a nine-figure guarantee like those of Burnes and Wheeler.

Instead, both hurlers figure to enter the open market hoping to re-establish themselves as front-of-the-rotation talents after facing adversity in recent years. Scherzer and Buehler landed the 33rd and 37th spots on MLBTR’s annual Top 50 MLB Free Agents list this winter, as we predicted one-year deals worth $16MM and $15MM respectively for each player. While both hurlers boast ace-level pedigrees and could wind up signing similar contracts this winter, the pair took different paths to get to this point over recent years and their unique challenges and assets could inform the preferences of prospective suitors.

Scherzer’s struggles in recent seasons have been almost entirely about health rather than performance. After turning in 11 utterly dominant starts for the Dodgers down the stretch following a trade from the Nationals at that summer’s trade deadline, the veteran right-hander’s season came to an abrupt end when he was forced out of Game 2 of the NLCS due to a dead arm after just 4 1/3 innings of work. Scherzer was unable to bounce-back in time to pitch again for L.A. in that series and ultimately departed the club on the heels of their loss to the eventual World Champion Braves in the series.

After landing with the Mets on a three-year guarantee worth $130MM, Scherzer turned in a dominant 2022 campaign for New York but was limited to just 23 starts due to oblique issues. It was the fewest starts he had made in a full season during his career, and his 145 1/3 innings of work, while hardly out of the ordinary for a starter in recent years, was similarly a full-season career low. The right-hander bounced back in terms of volume in 2023, making 27 starts for the Mets and Rangers throughout the regular season, but suffered on the performance front as he posted a somewhat middling 3.77 ERA (112 ERA+) in 152 2/3 innings of work. Those results improved significantly (3.20 ERA, 135 ERA+) down the stretch following his trade to Texas, but much like 2021 Scherzer struggled with injuries late in the season and was hampered during the playoffs, ultimately pitching just 9 2/3 innings total during the club’s championship run.

While Scherzer’s declining volume and production were somewhat concerning, the future Hall of Famer was still clearly among the top pitchers in the sport even as he began to struggle with injury. Over those aforementioned two seasons, Scherzer combined for 50 starts where he posted an excellent 3.03 ERA (133 ERA+) with a 3.49 FIP and a 29.3% strikeout rate in 298 innings of work. That performance was good for 6.7 fWAR, good for 23rd among all starters across those two seasons and sandwiched between the likes of Max Fried and Clayton Kershaw.

Unfortunately for the veteran, however, things took a substantial turn for the worse in 2024 as he suffered from the first truly injury-plagued season of his career. After undergoing back surgery last offseason, Scherzer’s was expected to miss at least the first couple of months of action. That timetable was further delayed by nerve issues, and by the time shoulder fatigue brought his season to an early end in September he had made just nine total starts this season. Those nine starts saw Scherzer pitch effectively, though not close to the ace-level production he had flashed even two years prior. In 43 1/3 innings of work this season, he pitched to a 3.95 ERA with a 4.18 FIP, striking out 22.6% of opponents faced while walking just 5.6%.

Looking ahead to 2025, it’s certainly easy to imagine Scherzer providing high quality production whenever he’s on the field, given the league average results he posted while fighting through injury this year and his pedigree as a three-time winner and six-time finalist of the Cy Young award. With that being said, the veteran will celebrate his 41st birthday in July of 2025, and his increasingly detrimental injury woes in recent years leave plenty of questions about just how many starts Scherzer can be counted on for in 2025, particularly in the postseason given the injury questions he faced in 2023, 2021, and even 2019 with the Nationals.

By contrast, Buehler comes with far fewer questions regarding his overall health. That’s to be expected from a player who is a decade and a day Scherzer’s junior. That’s not to say Buehler hasn’t had health issues of his own, of course, as Buehler had nearly two full calendar years of his career wiped out by Tommy John surgery. Buehler returned to the mound for the Dodgers on May 7 of this year after having last pitched in a major league game on June 10 of 2022. The righty has had few injury woes throughout his career aside from his two career elbow surgeries, with a bout of hip inflammation this year and a rib injury back in 2018 representing the only other significant injuries of his big league career.

With that being said, it’s worth noting that the aforementioned Tommy John surgery was actually the second of Buehler’s pitching career. It’s not uncommon for players to struggle after going under the knife a second time, though some pitchers such as Nathan Eovaldi and Jameson Taillon have undergone the procedure twice and gone on to be effective for years following their second surgery. Buehler also averaged 95 mph on his fastball in 2024, an encouraging sign as it’s right in line with his average prior to going under the knife.

That’s not to say Buehler lacks question marks, however. The right-hander’s 2024 season was nothing short of atrocious. He surrendered a 5.38 ERA and 5.54 FIP that were both more than 30% worse than league average by ERA- and FIP-, while his 18.6% strikeout rate and 8.1% walk rate were both the worst marks of his career since he became a full time player in 2018. While Buehler’s solid 15 innings of work during the playoffs (3.60 ERA, 3.50 FIP) offer some reason for optimism, particularly as he struck out a third of his opponents in the NLCS and World Series, his atrocious regular season results are difficult to ignore. While Scherzer seems to be a reasonable bet to produce when healthy enough to take the mound, Buehler will need to improve his overall production substantially to be an even league average starter next year even as he flashed his front-of-the-rotation upside late in the Dodgers’ championship run this postseason.

If your team was in the market for a bounce-back starter this winter, which would you rather sign? Would you value Scherzer’s strong results and lengthy track record of success when healthy despite his age and injury questions, or would you prefer Buehler’s youth and upside despite his brutal results in 2024?

Knee problems have bothered Alvarez for much of his career, and he had arthroscopic surgeries on both of his knees back in 2020.  The Astros have primarily used Alvarez as a DH in a nod to these knee issues, and while there isn’t yet any indication that today’s injury is anything more than a bruise, it certainly isn’t a good sign to see one of Houston’s top hitters suddenly facing a health concern just a week away from the playoffs.  Alvarez is enjoying another tremendous season, with a 35 homers and a .305/.309/.564 slash line in a career-high 636 plate appearances entering today’s action.

More from around the AL West…

• Gregory Santos could be activated off the Mariners’ 15-day injured list within the next couple of days, the Seattle Times’ Adam Jude reports (via X).  Between a season-opening lat strain and then a bout of biceps inflammation that has kept him sidelined since July 31, Santos has appeared in only six games for Seattle this year, delivering a 6.75 ERA in 5 1/3 innings of work.  Santos has also tossed 5 1/3 innings during his six Triple-A rehab outings, with a 1.69 ERA but also with more walks (seven) than strikeouts (six).  Acquired from the White Sox in a notable February trade, Santos hasn’t done much in his first season with the Mariners, but there’s a chance for some late heroics if he can return in time to help the M’s sneak into a playoff berth.
• Speaking of injury-plagued seasons, Max Scherzer’s 2024 campaign officially ended when a hamstring strain sent him to the Rangers’ 15-day injured list yesterday.  Limited to a career-low 43 1/3 innings in 2024, Scherzer has already stated that he wants to return for an 18th big league season, and he told MLB.com’s Kennedi Landry (X link) and other reporters today that he is open to returning to Texas.  Jacob deGrom, Jon Gray, Tyler Mahle, Jack Leiter, Kumar Rocker, Dane Dunning, and Cody Bradford are all lined up as rotation locks or candidates for the Rangers next season, so on paper, there might not be room for a reunion with Scherzer even on a one-year deal.  That said, there’s also enough uncertainty within that projected depth chart that Texas might want still seek out more arms, and a pitcher with Scherzer’s track record still has plenty of upside even at age 40.
• Ben Gamel was placed on the 10-day injured list earlier this week due to a fractured fibula, and in his weekly appearance on the Astros’ pregame radio show, GM Dana Brown confirmed that Gamel will “most likely” not be available for the postseason.  Between Gamel’s injury, Chas McCormick’s fractured hand, and the new uncertainty about Alvarez’s status, Houston’s outfield is suddenly facing depth issues as the playoffs approach.

The news brings to an end Scherzer’s 2024 season. In all, Scherzer managed just nine starts and 43 1/3 innings of work this year, the first time since his rookie year back in 2008 where he pitched less than 145 1/3 innings in a 162-game season. His results weren’t especially dominant even when healthy enough to take the mound, either. His 92.6mph average on his fastball was the lowest of his career, while a 22.6% strikeout rate, 3.95 ERA (100 ERA+), and a 4.18 FIP were all closer to pedestrian than elite. Since being acquired from the Mets in exchange for infield prospect Luisangel Acuna last summer, the veteran righty has pitched to a 3.57 ERA with a 3.79 FIP in 88 1/3 innings of work for Texas.

Those may turn out to be the only innings Scherzer pitches in a Rangers uniform. The future Hall of Famer’s contract in Texas runs only through the end of the current campaign, and he now appears ticketed for another trip through free agency. Scherzer celebrated his 40th birthday back in July and has dealt with a number of injury concerns this year ranging from offseason back surgery to nerve irritation in his throwing hand and triceps area on different occasions, but that hasn’t stopped the veteran from planning to continue pitching next year.

Even on the heels of the first injury-marred campaign of his career, Scherzer’s overall resume speaks for itself: the veteran boasts more than 3400 strikeouts in his career to go with eight career All-Star appearances, three Cy Young award wins, and three additional years wherein he was a finalist for the awards. The right-hander hasn’t posted an ERA north of 4.00 or a below-average ERA+ since 2011, and since then he sports a 2.95 ERA and 3.00 FIP, to say nothing of his career 3.78 ERA and 28.8% strikeout rate in the postseason and the two World Series rings he’s earned as a result of those 143 innings of work in the playoffs over the years. Still, at Scherzer’s age and coming off a platform season that raised plenty of questions about his ability to act as the workhorse starting pitcher he was throughout his 30s now that he’s entering his 40s, it’s not entirely clear what sort of market awaits the veteran ace in free agency.

Texas has exciting young arms like Kumar Rocker and Jack Leiter coming up from the farm system to join a 2025 rotation corps that includes Dunning, Jacob deGrom, Jon Gray, Cody Bradford, and Tyler Mahle, but a return to the Rangers certainly can’t be ruled out. After all, Scherzer is likely to be joined in heading for free agency by Nathan Eovaldi, Andrew Heaney, and Jose Urena. That quartet has combined to start 74 of the Rangers’ 154 games to this point in the season, or nearly half of the club’s contests. Given the combination of youth and lengthy injury histories at play in Texas’s current rotation group headed into next year, it would hardly be a surprise to see the club prioritize adding at least one arm to help carry the load of the departing starters.

Of course, a player with Scherzer’s storied resume could easily draw interest from plenty of other clubs in the league the league. The right-hander’s former teams in Detroit and D.C. are both seemingly ready to take the next step after lengthy rebuilding periods and could benefit from adding a veteran arm to their young rotations, and Scherzer’s hometown Cardinals appear likely to try and revamp their rotation mix behind staff ace Sonny Gray after their second-straight disappointing season. Given the ace’s talent when healthy and the fact that his age and recent injury history appear likely to limit him to a short-term deal, there’s countless teams that could reasonably be positioned to take a chance on the 40-year-old future Hall of Famer this winter.

Sept. 10: Jacob deGrom makes his season debut on Friday. The Rangers announced that the two-time Cy Young winner will start that evening’s game in Seattle. It will be his first major league appearance since April 2023. deGrom underwent Tommy John surgery last June.

While deGrom’s return comes too late to give Texas any hope of a playoff push, it’s part of what should be a very exciting series. The Rangers will turn to top prospect Kumar Rocker for his MLB debut in Thursday’s opener. deGrom goes the following night. Manager Bruce Bochy told the beat this evening that Max Scherzer will be reinstated from the 15-day injured list to start on Saturday (X link via Shawn McFarland of the Dallas Morning News). Texas will need to create space on the 40-man roster for both Rocker and deGrom.

deGrom has gotten through four rehab starts within the past few weeks. He has mowed down minor league hitters, striking out 15 while allowing only five baserunners over 10 2/3 innings. deGrom tossed four scoreless innings in just 49 pitches with Double-A Frisco on Saturday. Kennedi Landry of MLB.com wrote over the weekend that the Rangers had envisioned deGrom throwing somewhere around 60 pitches in that outing, though they ultimately elected to cap him at four innings when he pitched so efficiently. That could point to a potential 65-75 pitch count during this week’s start.

The Rangers should get three or four starts from deGrom before the end of the season. They’re not going to be of much significance in the standings (beyond the indirect effect of playing the Mariners, a fringe contender, at least once). Getting deGrom back for a few starts should at least give the pitcher and the front office some comfort going into the offseason. deGrom had battled a handful of arm issues late in his Mets tenure. He only managed six starts and 30 1/3 innings with Texas before suffering the significant elbow injury.

Few players are more important to the Rangers’ hope of a return to contention in 2025. deGrom may still be the best pitcher on the planet when healthy. He was utterly dominant for the Mets when he was able to pitch. He’d carried that form over in his first month in a Texas uniform, working to a 2.67 earned run average while striking out almost 40% of batters faced.

deGrom is going into the third season of a five-year, $185MM free agent deal. He’ll make $40MM next season, followed by successive salaries of $38MM and $36MM through 2027. The Tommy John surgery triggered a conditional team option in his deal for 2028. That’s valued at $20MM, though deGrom could push it to $30MM if he finishes in the top five in Cy Young balloting in any of the next three years.

Scherzer, meanwhile, has been out since the start of August because of a shoulder issue. He’d also missed most of the season’s first half rehabbing offseason back surgery and battling a nerve problem in his throwing hand. Scherzer has been limited to eight starts this season, turning in a 3.89 ERA across 39 1/3 innings. The future Hall of Famer will be a free agent next offseason. Scherzer has already declared he intends to continue pitching; he’ll be one of the top risk/reward plays in the starting pitching class.

“If it all goes well, he’ll be pitching for us next time around,” manager Bruce Bochy told MLB.com’s Kennedi Landry and other reporters.  “It’s pretty cool because it’s been a long road as these guys go through the rehab on the Tommy John.”

DeGrom had his Tommy John surgery in June 2023, and last pitched in a big league game on April 28, 2023.  After signing a five-year, $185MM free agent contract with Texas during the 2022-23 offseason, deGrom’s only contribution to the Rangers’ World Series season was six starts and 30 1/3 innings, albeit with a very impressive 2.67 ERA and his typically excellent strikeout and walk rates.

Statistics compiled during minor league rehab stints should always be taken with a grain of salt, but deGrom has looked quite sharp in posting an 0.84 ERA over 10 2/3 total innings in the minors.  As Landry noted, deGrom has been so dominant that he hasn’t been able to entirely hit his assigned rehab checkpoints.  In his start on Saturday, Bochy said deGrom was assigned for four innings or 60 pitches, yet deGrom breezed through Double-A opponents on just 49 pitches — the most he has thrown in any of his four rehab starts.

As the season enters its final three weeks, the Rangers’ title defense has resulted in only a 70-74 record and a longshot bid at a wild card berth.  DeGrom won’t be returning to a pennant race, but there’s some obvious benefit in getting back on a big league mound and shaking off some rust in advance of a hopefully normal offseason, and then a standard ramp-up in Spring Training.  At age 36 and with just 186 2/3 MLB innings pitched since Opening Day 2021, deGrom’s health history will always make him something of a question mark, yet he has continued to deliver whenever he has been able to pitch.

DeGrom could soon be joined by another veteran ace in Max Scherzer, whose minor league rehab stint got underway Saturday at Triple-A with four hitless innings of work on 53 pitches.  Right shoulder fatigue and then triceps discomfort has kept Scherzer on the injured list since the start of August, but a mechanical fix seems to have corrected his triceps issue, and Scherzer looked to be in good form on Saturday.

It seems possible that Scherzer could rejoin the Rangers as early as this week’s road trip, depending on whether or not the team feels he needs any more rehab work to more fully build his pitch count.  The Rangers could also activate Scherzer and then allow him to rebuild at the MLB level, either on a limited innings count or with a piggyback pitcher working behind Scherzer.

Heading into the season, Texas planned to have deGrom, Scherzer (who was then recovering from offseason back surgery), and Tyler Mahle (Tommy John surgery) all back around the middle of the year, providing the rotation with some reinforcements down the stretch.  While a few setbacks delayed these pitchers on that projected timeline, the bigger problem was other injuries and a lack of hitting that torpedoed the Rangers’ season.

Ironically, this planned surplus of pitching has now come at a time when the Rangers might prefer to look at their future arms.  One such hurler is top prospect Kumar Rocker, who has opened some eyes since his own return from a May 2023 Tommy John surgery.  The third overall pick of the 2022 draft has an 0.46 ERA over 19 2/3 innings in Double-A ball this season, and an 1.80 ERA in 10 innings since being promoted to Triple-A Round Rock.

These numbers have been impressive enough that Rangers GM Chris Young told reporters (including Evan Grant of the Dallas Morning News) that the team hadn’t closed the door on the possibility of Rocker making his big league debut at some point before the 2024 campaign is over.  Grant ran through the various factors involved, including Rocker’s rough 50-inning cap in his first season back from TJ surgery, and the fact that Texas would be putting Rocker on the 40-man roster perhaps earlier than necessary.  With three weeks remaining in the season, there’s still time for Rocker to bank a few more Triple-A innings, and if he keeps forcing the issue, the Rangers still have time to perhaps have the right-hander make a cameo after the minor league season is over.

Blanco’s unexpected emergence has been a revelation for a Houston team hit hard by rotation injuries earlier this season.  He threw a no-hitter against the Blue Jays in his very first start of 2024, setting the tone for a year that has seen him post a 3.03 ERA over 148 1/3 innings.  The concern is that Blanco has already topped his previous high of 125 1/3 innings across the majors and minors in 2023, and Houston naturally wants to keep him fresh for the playoffs.  The Astros’ rotation has been so dominant in recent weeks that they can afford to lose Blanco’s production, and there’s plenty of upside to using Blanco as a bullpen weapon down the stretch and into October.

More items from around the AL West….

• It has been over a month since Max Scherzer last pitched, as he was dealing with right shoulder fatigue and then had a Double-A rehab start on August 23 canceled for unspecified reasons.  Scherzer discussed the situation with MLB.com’s Kennedi Landry and other reporters this weekend, saying he was hampered by a nerve problem in his triceps area, but it wasn’t actual nerve damage, as tests revealed.  A change to Scherzer’s throwing motion might’ve “solved this,” as “there was something mechanically going on with my elbow and elbow retraction that was making that radial nerve of my tricep get irritated,” Scherzer said.  “Yesterday, I got on the mound to do a full bullpen and no issue….Structurally, I’m fine.  Strength, I’m fine.  I don’t have an injury here.  This was just a nerve irritation.”  Scherzer is now hopeful that he’ll be able to properly resume his rehab program within the week, and he believes he’ll return to the Rangers rotation before the season is over.
• Jose Soriano was placed on the 15-day injured list on August 17, but he won’t be activated when first eligible.  It isn’t yet clear if Soriano will return at all in 2024, as Angels GM Perry Minasian told the media (including MLB.com) that the team is considering shutting Soriano down.  The right-hander was sent to the IL due to arm fatigue, which isn’t unexpected given that Soriano has thrown a career-high 113 innings this season.  His previous high was 82 1/3 innings in the minors in 2019, before two separate Tommy John surgeries put Soriano on the shelf for almost three full years.  He made his big league debut as a reliever in 2023 and moved into the rotation this season, posting a very respectable 3.42 ERA across his 113 frames.  With some solid results already in the books, the Angels might opt to just let Soriano get a head start on his 2025 preparations rather than ramp him back up for another outing or two this season.

It’s been a challenging season for Scherzer, who has never really dealt with a significant injury before. Apart from his 2008 debut and the shortened 2020 season, he has never thrown less than 145 1/3 innings in a major league season. He logged at least 170 frames in each full season from 2009 to 2021.

But he is certainly going to fall short of that range this year. He has thrown 39 1/3 innings in the majors and he’s running out of time to add to that total. He underwent back surgery in the offseason and it was initially hoped that he could be back at some point in May, but that didn’t come to pass.

He began a rehab assignment in late April but that was halted after just one outing due to some soreness in his right thumb. Grant relayed on May 11 that Scherzer was dealing with a nerve issue running down his arm and had received a cortisone injection. Grant provided an update in a May 15 column, noting that Scherzer had received a Botox injection, a treatment for neurogenic thoracic outlet syndrome but also other nerve pain. In a May 28 column, Grant noted that neurogenic TOS normally features pain going from the shoulder to the finger but Scherzer’s case was the opposite, with pain going up his arm from his thumb. In another update on May 31, Grant again mentioned neurogenic TOS but noted that Scherzer has maintained the issue is not TOS.

Scherzer was eventually able to get healthy enough to get on the mound. He made two more rehab starts in June and was reinstated from the injured list that month. He made eight starts at the big league level, throwing the aforementioned 39 1/3 innings, allowing 3.89 earned runs per nine. But in the first week of August, he landed back on the IL due to some right shoulder fatigue. As mentioned, he was planned to start a rehab assignment tonight but that won’t happen now.

It’s undoubtedly a frustrating experience for Scherzer with the constant starting and stopping this year, but there’s little reason for the club to push him at this point if he’s not 100%. The club is 59-69 and 10.5 games back of the Astros in the West. Both the Playoff Odds at FanGraphs and the PECOTA Standings at Baseball Prospectus put their chances of cracking the postseason at less than a half of a percentage point.

With their season more or less on life support, the club and Scherzer can focus on his long-term health. As of last week, the 40-year-old said he was planning to pitch again in 2025. He won’t take the hill tonight and further developments will undoubtedly be forthcoming in the next few weeks.

Scherzer is scheduled to hit free agency at season’s end and is health status will likely play a key role in how the winter plays out for him. Plenty of clubs would be interested in him based on his amazing track record but the mention of neurogenic TOS will undoubtedly raise some flags. Last summer, Jesse Dougherty of The Washington Post looked at the two different kinds of TOS and why the results are often so divergent. Merrill Kelly once had venous TOS but was able to recover and has pitch at a high level for years afterwards. Whereas neurogenic TOS is often more debilitating, with pitchers like Stephen Strasburg significantly hampered by the condition.

Again, Scherzer has insisted he is not dealing with neurogenic TOS, though he does have a nerve issue of some kind. Whatever is ailing him, it’s been a significant roadblock this year. He will undoubtedly be exploring all avenues with medical experts in the coming weeks to find a path forward towards his goal of pitching next year. As of today, he has a 3.16 ERA in almost 3,000 career innings pitched and is tenth on the all-time strikeout list.

Mahle, now 29, underwent Tommy John surgery last summer just before hitting free agency for the first time in his career. The Rangers then signed him to a two-year, $22MM deal, knowing that they wouldn’t be able to count on him to join the club until some point in the middle of the 2024 season at the earliest. He was on the IL until two weeks ago and has since made three starts. He went five innings in the first of those, then four and two thirds, followed by just three innings in Sunday’s game.

It’s unclear if the shoulder was bothering him in his last outing or has been nagging at him since. While he was removed after just three innings, he also allowed four earned runs on six hits while recording just one strikeout, so his removal might simply have been about his performance rather than his health.

Shoulder issues have been a problem for him before, as he only made six starts after July 2 in the 2022 season due to a strain and some inflammation. Between those shoulder issues and his recent Tommy John layoff, it’s been three straight seasons of having a truncated workload.

The Rangers have fallen back in the standings lately and are now 11 games back of the Astros in the West and 12.5 games back of a Wild Card spot. Both the Playoff Odds at FanGraphs and the PECOTA Standings at Baseball Prospectus give them just a 0.4% chance of cracking the postseason at this point.

With the club’s season on the ropes, they can make their decisions based on optimizing results next year. Ideally, Mahle would be building up his workload since he hasn’t pitched much in recent years, but pitching through an injury would run the risk of aggravating a shoulder that has given him problems in the past, so it seems the club has decided a breather is the best decision for now. Assuming the issue isn’t major, perhaps he can return for the final few weeks and log some innings in September.

Going forward, the club’s rotation could be facing notable changes. Jacob deGrom is starting a rehab assignment this week and Max Scherzer will be as well, per Landry on X. When those two come back, they will likely slot into the rotation with Gray, Nathan Eovaldi and Andrew Heaney, with Cody Bradford and Dane Dunning also in the mix and perhaps Mahle coming back down the line.

Looking ahead to next year, Scherzer and Heaney are impending free agents with Eovaldi perhaps heading to the open market along with them. Eovaldi’s contract has a conditional $20MM player option that he unlocks if he totals 300 innings pitched over 2023 and 2024 or finishes in the top five in Cy Young voting this year. Even if he unlocks that option, which is possible since he’s at 271 innings since the start of last year, he might turn it down and elect free agency since he’s having a strong season and could look for a bigger guarantee in free agency.

Without those three, the Texas rotation for 2025 projects to include deGrom, Mahle and Gray. The latter two, as mentioned, are coming off lengthy Tommy John rehabs and could have workload concerns next year. Bradford has also missed significant time this year, due to a low back strain, and only has 14 big league starts to his name. Dunning has often been in the club’s swingman/sixth starter role, moving between the bullpen and rotation as needed. Prospects Jack Leiter and Owen White are on the 40-man roster but both have ongoing control issues.

The Rangers are still the reigning World Series champions for a few more months but the title defense has obviously not been what they had in mind. Perhaps that will lead them to shake up their rotation mix in the offseason, as there’s plenty of uncertainty in next year’s group.

While things are looking promising for Verlander, Luis Garcia is more of a question mark.  The Athletic’s Chandler Rome wrote (via X) that as of Friday, Garcia hadn’t yet resumed throwing since he was shut down due to soreness over two weeks ago.  This is the second time Garcia has hit a setback in his recovery from Tommy John surgery, and since Garcia went under the knife in May 2023, a normal rehab timeline would’ve had him ready to return to the majors by this point over 15 months past his procedure date.  Though the Astros have said Garcia might return as a reliever rather than as a starter, he is running short on time to fully ramp up his readiness to rejoin Houston’s pitching staff in any capacity.

More from around the American League…

• Twins athletic trainer Nick Paparesta updated reporters (including The Athletic’s Dan Hayes) about several injured Minnesota players on Saturday, including Byron Buxton and Chris Paddack.  Buxton received a cortisone shot in his inflamed right hip and recently worked out in a pool, so Paparesta feels “we’re kind of heading in the right direction.”  This comes as a relief given Buxton’s long history of injury problems, including a more serious hip issue in 2022 that Paparesta feels may have created scar tissue related to Buxton’s current discomfort.  As for Paddack, he is set to undergo an MRI on August 27, which will be his second scan since a left forearm strain sent him to the 15-day injured list on July 17.  More will be known on Paddack’s timeline if the next MRI comes back clean, and he has already started playing games of catch in preparation to return to Minnesota’s staff before the season is over.
• Three of the Rangers’ injured veteran starters took steps in their recoveries over the weekend, as Max Scherzer threw a bullpen session today and Jacob deGrom and Jon Gray each threw three-inning simulated games on Saturday.  Gray seems to be the closest to returning, as he told MLB.com that he could return as a reliever during the Rangers’ series with the Pirates that begins tomorrow, if he isn’t lined up for a proper start during a series with the Guardians that gets underway Friday.  A right groin strain sent Gray to the 15-day IL on July 29, while deGrom could begin a Double-A rehab assignment this week in his first game action since undergoing Tommy John surgery in June 2023.  Scherzer hasn’t pitched since July 30 due to shoulder fatigue, and Texas manager Bruce Bochy said it hasn’t yet been decided if Scherzer will also embark on a rehab assignment next, or if he’ll first take part in a live batting practice session.
• Tarik Skubal had another quality start tonight in the Tigers’ 3-2 win over the Yankees, as the star southpaw limited New York to one run (on three hits and four walks) over six innings of work.  Skubal is up to a career-high 155 1/3 innings pitched, and manager A.J. Hinch told MLB Network’s Jon Morosi and other reporters that Sunday “could very well be his last start on regular rest” this season.  Since Detroit is all but out of the wild card race, the team has no real reason to put too many extra miles on Skubal’s arm, though naturally the team isn’t going to shut him down completely as he pursues the AL Cy Young Award.

Unsurprisingly, it doesn’t seem Scherzer is comfortable with this season as a swan song. The eight-time All-Star told reporters that he expects to continue playing in 2025 (link via Evan Grant of the Dallas Morning News). “When I’m out there, I’ve been able to compete,” Scherzer noted. “I can still pitch at a high level. I look at things like my slider, which I went into the season wanting to fix, and it’s been really good. I still see myself as able to compete and win.”

Scherzer, who turned 40 in July, has been the fourth-oldest player in the majors this season. Two-time teammate Justin Verlander, Jesse Chavez, and Charlie Morton are older. Scherzer nevertheless remains capable of performing well when healthy. He has turned in a 3.89 ERA with a solid 24.1% strikeout percentage and an excellent 5.1% walk rate across 39 1/3 innings. Those aren’t vintage Scherzer numbers, yet it’s still quality mid-rotation production. That’s despite him pitching at what appears to be less than full strength. His velocity was down a tick relative to last season, which could be attributable to the various injuries through which he has battled.

An injury-plagued year is going to raise more concern for a player of Scherzer’s age. Still, this will be the first season (excluding the shortened schedule) in which he hasn’t reached 145 innings since his 2008 rookie year. While he battled injuries during last year’s postseason and was eventually pulled from the World Series roster, he still combined for 162 1/3 innings between the Mets and Rangers in the regular season and playoffs.

Texas is all but officially buried in the playoff race this year, but Scherzer came out of a bullpen session without issue today and looks to be on track for a return from the injured list relatively shortly. He could make another six or seven starts to finish the season.

Scherzer seems set on continuing his Hall of Fame career for an 18th year. There’s nevertheless uncertainty about where he’ll be playing. He’s in the final season of the three-year, $130MM free agent contract which he signed with New York in 2021. He’ll return to the open market during the upcoming offseason. Scherzer certainly isn’t going to match the three-year term or record-setting $43.333MM average annual value of his current contract, but he should still command a strong one-year deal.

Players like Jack Flaherty, Frankie Montas and Luis Severino all landed guarantees between $13MM and $16MM as rebound candidates last offseason. Scherzer is much older than that trio but he’s had a more accomplished career and has the ability to turn in an ace-caliber year. A deal in the $15-20MM range on a high-payroll club with legitimate World Series aspirations could be viable. That might be Texas, though they’ll need to make other moves in the rotation and strengthen the bottom part of the lineup if they’re to make a renewed push to contend.

By placing Giolito, Lopez, Cron, Grichuk, Leone, Matt Moore, Hunter Renfroe and Tyler Anderson on waivers, the Angels positioned themselves to A) save an enormous amount of money, B) potentially dip back under the luxury tax threshold (they succeeded), and C) impact several postseason races ... just not in the way they originally envisioned. For those who don't recall, the Guardians claimed Giolito, Lopez and Moore. Renfroe was claimed by the Reds. Leone went to the Mariners. Grichuk and Anderson were not claimed.

Last week, MLBTR's Darragh McDonald previewed a handful of veterans who could hit waivers in just this fashion later this month. Since Darragh wrote that piece, one team has emerged as an even likelier candidate to go down this road; as the Astros have gone on an eight-game winning streak and the Mariners have kept in arm's reach, the Rangers have fallen to a daunting 10 games back in the AL West and 10.5 back in the Wild Card hunt. FanGraphs gives the Rangers a 0.6% chance of reaching the postseason. Baseball Prospectus' PECOTA is more bullish ... at 2.4%. Texas isn't mathematically eliminated, but they're not far off.

As Darragh noted last week and as both Ken Rosenthal of The Athletic and Jon Becker of FanGraphs have explored this week, there's an argument that the Rangers should jettison some of their impending free agents and cut back costs. In his column, Becker looked at how much money the Rangers would save by placing their impending free agents on waivers two days before the Aug. 31 postseason eligibility deadline. Rosenthal noted within his column that there's no clear path to dipping under the luxury tax for the Rangers, "so their only motivation would be to save on salary."

Technically that's true, but it's also not impossible for the Rangers to duck under the threshold without placing their entire roster on waivers for the taking. While sneaking under the tax threshold is a tall order, it could potentially be done without completely decimating next season's roster. Let's take a look at how they could get there and at what type of benefits they'd receive for doing so.

Unlock Subscriber-Exclusive Articles Like This One With a Trade Rumors Front Office Subscription

BENEFITS

• Access weekly subscriber-only articles by Tim Dierkes, Steve Adams, and Anthony Franco.
• Join exclusive weekly live chats with Anthony.
• Remove ads and support our writers.
• Access GM-caliber tools like our MLB Contract Tracker